Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer
Madan RA, Karzai FH, Al Harthy M, Petrylak DP, Kim JW, Arlen PM, Rosner I, Theoret MR, Cordes L, Bilusic M, Peer CJ, Dawson NA, Couvillon A, Hankin A, Williams M, Chun G, Owens H, Marte JL, Lee M, Tomita Y, Yuno A, Trepel JB, Lee S, Steinberg SM, Gulley JL, Figg WD, Dahut WL. Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer. BJU International 2020, 127: 435-444. PMID: 32969563, PMCID: PMC8265825, DOI: 10.1111/bju.15227.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerDocetaxel/prednisoneCastration-resistant prostate cancerPhase 1 studyProstate cancerDose of cabozantinibEfficacy of cabozantinibPalmar-plantar erythrodysesthesiaPhase 1/2 trialPhase 2 studyOverall survival timeDocetaxel/Median TTPNeutropenic feverPoor accrualThromboembolic eventsMore patientsRandomized studyMedian timeMulticentre studyGrade 3Survival timeCabozantinibPrednisonePatients